Download or read book Value Creation and Distribution in Biotech and Pharma Licensing Deals written by Jeremy A. Marti and published by . This book was released on 2018 with total page pages. Available in PDF, EPUB and Kindle. Book excerpt: This thesis investigates the wealth implications of licensing transaction announcements in the biotech and pharma industry for both the in- and out-licensing firm. Based on a matched sample of 148 transactions during the 5-year period from June 2013 to May 2018, an event study and complementary regression analyses are conducted to evaluate the drivers of value creation and distribution between deal parties. The empirical findings emphasize the importance of licensing transactions in the biotech and pharma value chain as both the in- and out-licensing parties experience significant wealth gains (CAAR-10,10 of 1.0% and 7.8%, respectively). In addition, the regression analysis supports the perception of licensing transactions as a measure of risk transfer, as out-licensing firms benefit with increasing deal size, while the wealth effects of in-licensing companies are negatively correlated. For out-licensing firms, the current ratio (as a liquidity proxy) and the economic cycle positively correlate with wealth effects, while the relative company size in a transaction is negatively correlated, implying a loss in bargaining power. For the in-licensing parties, the current ratio and relative company size (as liquidity and bargaining power proxy, respectively) positively correlate with wealth effects, while the analysis of the economic cycle implies a negative relation, suggesting that the pressure on valuation levels in phases of economic downturn benefits the in-licensing party.
Download or read book Value Creation in the Pharmaceutical Industry written by Alexander Schuhmacher and published by John Wiley & Sons. This book was released on 2016-04-11 with total page 511 pages. Available in PDF, EPUB and Kindle. Book excerpt: This practical guide for advanced students and decision-makers in the pharma and biotech industry presents key success factors in R&D along with value creators in pharmaceutical innovation. A team of editors and authors with extensive experience in academia and industry and at some of the most prestigious business schools in Europe discusses in detail the innovation process in pharma as well as common and new research and innovation strategies. In doing so, they cover collaboration and partnerships, open innovation, biopharmaceuticals, translational medicine, good manufacturing practice, regulatory affairs, and portfolio management. Each chapter covers controversial aspects of recent developments in the pharmaceutical industry, with the aim of stimulating productive debates on the most effective and efficient innovation processes. A must-have for young professionals and MBA students preparing to enter R&D in pharma or biotech as well as for students on a combined BA/biomedical and natural sciences program.
Download or read book Business Development for the Biotechnology and Pharmaceutical Industry written by Martin Austin and published by CRC Press. This book was released on 2016-04-08 with total page 202 pages. Available in PDF, EPUB and Kindle. Book excerpt: Business Development in the biotechnology and pharmaceutical industries accounts for over $5 billion in licensing deal value per year and much more than that in the value of mergers and acquisitions. Transactions range from licences to patented academic research, to product developments as licences, joint ventures and acquisition of intellectual property rights, and on to collaborations in development and marketing, locally or across the globe. Asset sales, mergers and corporate takeovers are also a part of the business development remit. The scope of the job can be immense, spanning the life-cycle of products from the earliest levels of research to the disposal of residual marketing rights, involving legal regulatory manufacturing, clinical development, sales and marketing and financial aspects. The knowledge and skills required of practitioners must be similarly broad, yet the availability of information for developing a career in business development is sparse. Martin Austin's highly practical guide spans the complete process and is based on his 30 years of experience in the industry and the well-established training programme that he has developed and delivers to pharmaceutical executives from across the world.
Download or read book Biotechnology Deals written by and published by . This book was released on 2005 with total page 148 pages. Available in PDF, EPUB and Kindle. Book excerpt: Inside the Minds: Biotechnology Deals is an authoritative, insider's perspective on the issues surrounding biotech deals, including mergers and acquisitions, collaborations, and the future of doing successful deals. Featuring lawyers, CEOs of funded biotech companies, and venture capitalists who invest in them, this book provides a broad, yet comprehensive overview of the art of doing successful deals from the experts themselves. From finding and capitalizing on opportunities to completing the deal, these authors articulate the finer points around doing biotech deals now and what will hold true into the future. The different niches represented and the breadth of perspectives presented enable readers to get inside some of the great legal minds of today as experts offer up their thoughts around the keys to success within this fascinating area.About Inside the Minds:Inside the Minds provides readers with proven business intelligence from C-Level executives (Chairman, CEO, CFO, CMO, Partner) from the world's most respected companies nationwide, rather than third-party accounts from unknown authors and analysts. Each chapter is comparable to an essay/thought leadership piece and is a future-oriented look at where an industry, profession or topic is headed and the most important issues for the future. Through an exhaustive selection process, each author was hand-picked by the Inside the Minds editorial board to author a chapter for this book.This book is by: Lee R. Brettman, M.D., FACP, Dynogen Pharmaceuticals, Inc.??Successful Strategies for Biotech Deals?Manish N Chapekar, Montreux Equity Partners??Building Successful Biotech Deals?Daniel Devine, Acceptys, Inc.??The Art of the Deal?Mark I. Gruhin, Schmeltzer, Aptaker & Shepard, PC??Mergers and Acquisitions, Collaborations, and Partnerships?James T. Gunton, NJTC Venture Fund??Strategies for Successful Deals?Johnny Humphreys, Gen Prime??Finding Success in Biotech?Roland H. Johnson, Piedmont Pharmaceuticals LLC??Making Your Way Through Biotech Dealings?Thomas G. Klopack, Self Employed, Former CEO of Aclara Biosciences??Keys to Success in Biotechnology?Gerard J. McGarrity, Ph.D., Intronn Inc.??Successful Biotech Deals?Mark Schwartz , Ph.D., Bayhill Therapeutics??Biotech Deal Strategies?Abhi-Shek Jain, WTP Capital, LLC??Secrets to Success?Alexis V. Lukianov, NuVasive, Inc.??Finding and Capitalizing on Opportunities?
Download or read book Quantitative Models in Life Science Business written by Jung Kyu Canci and published by Springer Nature. This book was released on 2022-11-16 with total page 131 pages. Available in PDF, EPUB and Kindle. Book excerpt: This open access book explores the field of life science business from a multidisciplinary perspective. Applying statistical, mathematical, game-theoretic, and data science tools to pharmaceutical and biotechnology business endeavors, the book describes value creation, value maintenance, and value realization in the life sciences as a sequence of processes using the quantitative language of applied mathematics. Written by experts from a variety of fields, the contributions illustrate the shift from a deterministic to a stochastic view of the processes involved, offering a new perspective on life sciences economics. The book covers topics such as valuing and managing intellectual property in life science, licensing in the pharmaceutical business, outsourcing pharmaceutical R&D, and stochastic modelling of a pharmaceutical supply chain. The book will appeal to scholars of economics and the life sciences, as well as to professionals in chemical and pharmaceutical industries.
Download or read book Approaches to Valuation of Pharmaceutical Licensing Deals written by Nigel Borshell and published by . This book was released on 2012 with total page 118 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Network Strategy written by Joel Baum and published by Emerald Group Publishing. This book was released on 2008-07-25 with total page 704 pages. Available in PDF, EPUB and Kindle. Book excerpt: Research at the intersection of social networks and strategic management identifies a range of performance-enhancing network position advantages - access to partners, information, innovation, and resources - that are distributed differentially across network positions. This book discusses network processes.
Download or read book PAREXEL s Pharmaceutical R D Statistical Sourcebook written by and published by . This book was released on 2005 with total page 350 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Biocapital written by Kaushik Sunder Rajan and published by Duke University Press. This book was released on 2006-04-24 with total page 360 pages. Available in PDF, EPUB and Kindle. Book excerpt: DIVAn ethnography about the work of genome scientists, entrepreneurs, and policy makers in biotech drug development in the United States and India./div
Download or read book The Business of Healthcare Innovation written by Lawton R. Burns and published by Cambridge University Press. This book was released on 2012-07-26 with total page 607 pages. Available in PDF, EPUB and Kindle. Book excerpt: Second edition of a wide-ranging analysis of business trends in the manufacturing segment of the healthcare industry.
Download or read book The Business of Healthcare Innovation written by Lawton R. Burns and published by Cambridge University Press. This book was released on 2005-08-25 with total page 400 pages. Available in PDF, EPUB and Kindle. Book excerpt: The first wide-ranging analysis of business trends in the manufacturing segment of the health care industry.
Download or read book The Alliance Revolution written by Benjamin Gomes-Casseres and published by Harvard University Press. This book was released on 1996 with total page 330 pages. Available in PDF, EPUB and Kindle. Book excerpt: More than we ever anticipated, alliances among firms are changing the way business is conducted, particularly in the global, high-technology sector. The reasons are clear: companies must increasingly pool their capabilities to succeed in ever more complex and rapidly changing businesses. But the consequences for managers and for the economy have so far been underestimated. In this new book, Benjamin Gomes-Casseres presents the first in-depth account of the new world of business alliances and shows how collaboration has become part of the very fabric of modern competition. Alliances, he argues, create new units of competition that do battle with one another and with traditional single firms. The flexible capabilities of these multi-firm constellations give them advantages over single firms in certain contexts, offsetting the advantage of a single firm's unified control. When managed effectively, alliances can strengthen a firm's competitive advantage and narrow the gap between leading firms and second-tier players. This often results in intensified rivalry, and the competition within an industry is transformed. Alliances often spread swiftly through an industry as firms jockey for advantage. Yet the very spread of alliances increases their costs and poses new limits on their use. Gomes-Casseres concludes that firms need to manage their constellations to enhance collaboration within their groups, while raising what he calls "barriers to collaboration" for rivals. These ideas are developed and illustrated through original case studies of alliances among U.S., Japanese, and European firms in electronics and computers, including Xerox, IBM, and Fujitsu as well as other small and large companies. The book should be of interest to business academics, managers, and general readers concerned with contemporary capitalism.
Download or read book WIPO ADR Options for Life Sciences Dispute Management and Resolution written by World Intellectual Property Organization and published by WIPO. This book was released on 2022-07-01 with total page 32 pages. Available in PDF, EPUB and Kindle. Book excerpt: This document has been developed by the WIPO Arbitration and Mediation Center (WIPO Center), as part of WIPO’s COVID-19 support package for member states. It takes into account input from WIPO Arbitrators and Mediators specialized in life sciences.
Download or read book Exchanging Value written by World Intellectual Property Organization and published by WIPO. This book was released on 2005 with total page 7 pages. Available in PDF, EPUB and Kindle. Book excerpt: Focuses on "the identification and acquisition, or transfer, through licensing, of technology that is owned by another by virtue of an intellectual property right." - page 5.
Download or read book Business Modeling for Life Science and Biotech Companies written by Alberto Onetti and published by Routledge. This book was released on 2014-03-21 with total page 233 pages. Available in PDF, EPUB and Kindle. Book excerpt: Most books on the biotechnology industry focus on scientific and technological challenges, ignoring the entrepreneurial and managerial complexities faced bio-entrepreneurs. The Business Models for Life Science Firms aims to fill this gap by offering managers in this rapid growth industry the tools needed to design and implement an effective business model customized for the unique needs of research intensive organizations. Onetti and Zucchella begin by unpacking the often-used ‘business model’ term, examining key elements of business model conceptualization and offering a three tier approach with a clear separation between the business model and strategy: focus, exploring the different activities carried out by the organization; locus, evaluating where organizational activities are centered; and modus, testing the execution of the organization’s activities. The business model thus defines the unique way in which a company delivers on its promise to its customers. The theory and applications adopt a global approach, offering business cases from a variety of biotech companies around the world.
Download or read book Industrial Clusters in Biotechnology written by Chiesa Vittorio Chiaroni Davide and published by Imperial College Press. This book was released on 2005 with total page 254 pages. Available in PDF, EPUB and Kindle. Book excerpt: Annotation - the preconditions for a cluster to grow (scientific base and/or industrial base, innovative financing, etc.); - the driving forces for cluster growth and development, i.e. the key factors of development (new company creation, IP rules, acceptance of biotech products, services and infrastructures, etc.); - best practices in cluster management (barrier removal, network creation, marketing, technology transfer, etc.).
Download or read book Managing Biotechnology written by Francoise Simon and published by John Wiley & Sons. This book was released on 2017-10-16 with total page 322 pages. Available in PDF, EPUB and Kindle. Book excerpt: A comprehensive overview of the new business context for biopharma companies, featuring numerous case studies and state-of-the-art marketing models Biotechnology has developed into a key innovation driver especially in the field of human healthcare. But as the biopharma industry continues to grow and expand its reach, development costs are colliding with aging demographics and cost-containment policies of private and public payers. Concurrently, the development and increased affordability of sophisticated digital technologies has fundamentally altered many industries including healthcare. The arrival of new information technology (infotech) companies on the healthcare scene presents both opportunities and challenges for the biopharma business model. To capitalize on new digital technologies from R&D through commercialization requires industry leaders to adopt new business models, develop new digital and data capabilities, and partner with innovators and payers worldwide. Written by two experts, both of whom have had decades of experience in the field, this book provides a comprehensive overview of the new business context and marketing models for biotech companies. Informed by extensive input by senior biotech executives and leading consultancies serving the industry, it analyzes the strategies and key success factors for the financing, development, and commercialization of novel therapeutic products, including strategies for engagement with patients, physicians and healthcare payers. Throughout case studies provide researchers, corporate marketers, senior managers, consultants, financial analysts, and other professionals involved in the biotech sector with insights, ideas, and models. JACQUALYN FOUSE, PhD, RETIRED PRESIDENT AND CHIEF OPERATING OFFICER, CELGENE “Biotech companies have long been innovators, using the latest technologies to enable cutting edge science to help patients with serious diseases. This book is essential to help biotech firms understand how they can–and must–apply the newest technologies including disruptive ones, alongside science, to innovate and bring new value to the healthcare system.” BRUCE DARROW, MD, PhD, CHIEF MEDICAL INFORMATION OFFICER, MOUNT SINAI HEALTH SYSTEM “Simon and Giovannetti have written an essential user’s manual explaining the complicated interplay of the patients who deserve cutting-edge medical care, the biotechnology companies (big and small) creating the breakthroughs, and the healthcare organizations and clinicians who bridge those worlds.” EMMANUEL BLIN, FORMER CHIEF STRATEGY OFFICER AND SENIOR VICE PRESIDENT, BRISTOL-MYERS SQUIBB “If you want to know where biopharma is going, read this book! Our industry is facing unprecedented opportunities driven by major scientific breakthroughs, while transforming itself to address accelerated landscape changes driven by digital revolutions and the emergence of value-based healthcare worldwide. In this ever-changing context, we all need to focus everything we do on the patients. They are why we exist as an industry, and this is ultimately what this insightful essay is really about.” JOHN MARAGANORE, PRESIDENT AND CHIEF EXECUTIVE OFFICER, ALNYLAM PHARMACEUTICALS “Since the mapping of the human genome was completed nearly 15 years ago, the biotechnology industry has led the rapid translation of raw science to today’s innovative medicines. However, the work does not stop in the lab. Delivering these novel medicines to patients is a complex and multifaceted process, which is elegantly described in this new book.”
